12:00 AM
 | 
Apr 25, 2011
 |  BC Week In Review  |  Clinical News  |  Regulatory

NKTR-102 regulatory update

FDA granted Orphan Drug designation for Nektar's NKTR-102 to treat ovarian cancer. The...

Read the full 42 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >